Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment

Acta Derm Venereol. 2007;87(5):401-5. doi: 10.2340/00015555-0260.

Abstract

High-dose chloroquine therapy for porphyria cutanea tarda is rarely used now because of its hepatic side-effects. The mechanisms of the effects and side-effects are poorly understood. We describe here effects, side-effects and long-term follow-up in 57 patients with a first-time diagnosis of porphyria cutanea tarda treated with 1-3 phlebotomies followed by 250 mg chloroquine phosphate daily for 7 days. A hepatotoxic reaction with high serum aminotransferases occurred in almost all patients. Within 3 months, clinical remission was obtained in all patients, and biochemical remission in almost all patients. Relapse occurred in 27 patients after 0.5-12 years. Subjective side-effects occurred more frequently in women, who also had higher maximum ALAT, ferritin and uroporphyrin values during treatment. Both subjective side-effects and ALAT during treatment correlated with pre-treatment uroporphyrin excretion and maximum uroporphyrin during treatment, but not with markers of hereditary haemochromatosis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alanine Transaminase / blood
  • Antimalarials / administration & dosage
  • Antimalarials / adverse effects*
  • Chemical and Drug Induced Liver Injury*
  • Chloroquine / administration & dosage
  • Chloroquine / adverse effects*
  • Dose-Response Relationship, Drug
  • Female
  • Ferritins / blood
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Phlebotomy
  • Porphyria Cutanea Tarda / blood
  • Porphyria Cutanea Tarda / therapy*
  • Porphyria Cutanea Tarda / urine
  • Porphyrins / urine
  • Recurrence
  • Remission Induction
  • Retrospective Studies
  • Risk Factors
  • Sex Factors
  • Transaminases / blood

Substances

  • Antimalarials
  • Porphyrins
  • Chloroquine
  • Ferritins
  • Transaminases
  • Alanine Transaminase